Fresenius SE & Co KGaA (FRE) Given a €83.00 Price Target by Sanford C. Bernstein Analysts

Fresenius SE & Co KGaA (FRA:FRE) received a €83.00 ($98.81) price objective from investment analysts at Sanford C. Bernstein in a research report issued on Tuesday. The firm presently has a “buy” rating on the stock. Sanford C. Bernstein’s target price indicates a potential upside of 20.85% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Warburg Research set a €80.00 ($95.24) price objective on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Monday, April 23rd. Barclays set a €81.00 ($96.43) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Tuesday. Kepler Capital Markets set a €63.00 ($75.00) target price on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Monday, April 23rd. Cfra set a €76.00 ($90.48) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Friday, May 4th. Finally, DZ Bank reiterated a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Friday, May 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of €77.24 ($91.96).

Shares of Fresenius SE & Co KGaA traded up €0.29 ($0.35), reaching €68.68 ($81.76), on Tuesday, Marketbeat reports. 679,827 shares of the company traded hands. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($71.62) and a 52 week high of €80.00 ($95.24).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply